Dates: September 22-25
Centro de Congressos de Lisboa
If you have any questions throughout the Meeting please contact Lindsey Lamont, who will be available on site.
Name: Lindsey Lamont
Phone: +1 203 206 1241
The CIRSE and IDEAS Scientific Programme Committees have combined cutting-edge science with innovative learning to produce an exciting educational programme. BTG is proud to participate in this important meeting and showcase our Interventional Oncology and Vascular portfolios.
No company endeavours to do more than BTG to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer and vascular conditions.
Interventional Oncology will be front and centre, highlighting our wide range of minimally-invasive, image-guided treatment options with specific focus on DC Bead LUMI™, TheraSphere™ and our new IceFx™ cryoablation system as part of the IO Ablation portfolio.
We are also excited to share that we will host multiple product theatre sessions on the BTG booth, seating 35 attendees with closed circuit audio. Click here to see a full list of sessions:
BTG's Vascular team is thrilled to showcase the new portable EKOS™ system. We will introduce and highlight the new line of crossing devices, providing a hands-on opportunity to track both the CenterCross and MicroCross devices through lesions.
Setting the standard in vascular therapies by making the most challenging cases easier
Antonio Nicolini attended the faculty of Medicine at the University of Genova, where he graduated in 1981 and obtained a post-graduate certificate in Radiology in 1986 at the University of Pavia. He was working at the Orthopaedic Institute G.Pini from 1984 to 1986, then at the Hospital of Cernusco S/N from 1986 to 1992. Since 1993, he has been working at Fondazione IRCCS Ospedale Maggiore Policlinico in Milan as Interventional Radiologist, and as chief of the Interventional Radiology Unit. He was a teacher at the School for Radiology’s Technicians in Monza from 1987 to 1991. He had been working as a tutor of the post-graduate course of Radiology of University of Milan from 2001 to 2006. He collaborated as a teacher for the Radiology course of the faculty of Medicine at the University of Milan in 1998-1999 and from 2001 to 2007.
He published scientific papers and he presented reports at international conferences on intervention oncology topics. Dr Antonio Nicolini attended CIRSE, GEST, WCIO and SIR. He also wrote papers on subjects such as Liver Int., Liver Transplant, World J Hepatology, JVIR, Expert Opinion Drug Delivery, Cardiovascular Interventional Radiology and Dig Liver Dis.
Professor Thierry de Baere is a full time dedicated to interventional oncology at Institut Gustave Roussy since 1991. He has excellent collaboration with surgery and medical oncology teams and is an active member of tumor board, allowing to develop many synergistic treatments including optimization of various intra-arterial therapies for primary and secondary liver tumors and locoregional therapies for innovative cancer treatment.
He has done clinical work dedicated to minimally invasive therapy for treatment of liver, lung and kidney tumors. Professor Thierry de Baere’s first RFA was in 1996. He does research and has a particular interest in portal vein embolization, intra-arterial therapy for liver cancer, percutaneous ablation in lung, liver and bones with RFA and cryoablation, as well as image guidance for IR.
Robert is a Surgical Oncologist from the University of Liverpool, United Kingdom, with a specialist interest in colorectal liver metastases. His main research interests are focused on optimising multidisciplinary decision making and surgical and non-surgical liver-directed therapies for advanced colorectal cancer. He also has a strong interest in patient stratification for surgical treatments of liver limited colorectal cancer– so called “precision surgery”.
Robert has published extensively on the role of DEBIRI in colorectal cancer, and was co-investigator in the prospective phase II PARAGON trial of neoadjuvant DEBIRI for resectable colorectal liver metastases. His group has performed novel translational research into the mechanism of action of DEBIRI, as well as optimal methods of assessing disease response after treatment.
Dr. Graumann is board certified in Radiology. He has special interests in Urogenital Radiology and Oncology Intervention especially renal cancer. Dr. Graumann currently serves as Head of section & Radiological Innovation Unit, Odense University Hospital, Denmark, is associate professor and the Physician Co-Leader of Radiology Research at University of Southern Denmark. Dr. Graumann has led and participated in a multitude of clinical trials and research. He has also written and contributed to a number of Scientific Books and published works within the subject of radiology, especially diagnostic and treatment of cancer.
Dr. Mert Dumantepe is an Associate Professor of Cardiovascular Surgery at Acibadem University School of Medicine. He completed his graduation from Istanbul University School of Medicine, Turkey 2001. He was trained in Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Research and Training Hospital. He did fellowship in the field of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Endarterectomy Programme and Heart Transplantation and Mechanical Asist Device Programme from University of California, San Diego School of Medicine, USA in 2015 and 2016. He is general secretary of Turkish Society of Cardiovascular Surgery – Pulmonary Vascular Disease and Pulmonary Hypertension working group.
His research interest includes; acute and chronic pulmonary embolism and venous thromboembolism endovascular treatment, peripheral arterial disease, thoracic and abdominal aortic vascular& endovascular surgery, pelvic congestion syndrome and venous insufficiency.
Dr. Keith Sterling is interventional radiologist who has been in practice in Northern Virginia since 1995. He is Chief of Cardiovascular & Interventional Radiology of the Association of Alexandria Radiologists and Medical Director of the Advanced Interventional Vein & Vascular Center. He maintains an appointment as Associate Professor of Radiology at George Washington University School of Medicine in Washington DC. He is also the Chairman of the Medical Affairs Council for the Inova Health System and a Fellow of the Society of Interventional Radiology.
Dr. Sterling graduated in 1985 from Northwestern University with a B.S. in Electrical Engineering & Computer Science. He earned his medical degree from New York Medical College in 1989. He served his medical internship at Columbia University College of Physicians & Surgeons in New York. He was a resident in Diagnostic Radiology at Mount Sinai Medical Center in New York and completed his fellowship in Vascular & Interventional Radiology at the Mallinckrodt Institute of Radiology/Washington University School of Medicine.
His research interests include: acute and chronic venous thromboembolic disease, pelvic congestion syndrome, venous insufficiency, peripheral arterial disease, vascular stents and uterine fibroids. He has been a principal investigator on numerous trials including SEATTLE II, OPTALYSE PE and ACCESS PTS.
Jurgen Futterer is Interventional-Radiologist at Radboud University Nijmegen Medical Centre, The Netherlands and full professor at the University Twente. His role focuses on imaging techniques in prostate cancer, with particular interest in magnetic resonance imaging (MRI)-guided interventions, such as MRI-guided laser-ablation, cryosurgery, and focused ultrasound surgery. Dr Futterer qualified at Radboud University Nijmegen in 2001, and completed his PhD on MRI techniques in the localisation and staging of prostate cancer in 2006. He was a radiology resident at the University Medical Centre, Nijmegen, in 2003, and completed a fellowship in interventional radiology/body MRI in 2009.
Dr Futterer is co-principal investigator of an international, multicentre study—the PCa-MAP trial—to investigate multiparametric MRI of the prostate in localising prostate cancer, and has published extensively on interventional MRI in prostate cancer in various journals and books chapters. He is an invited speaker at various international conferences (RSNA, ISMRM, SIR, ECIO, ECR). He has also introduced a robotic device for MRI-guided biopsy of the prostate, which has been established as a novel prostate intervention.
Dr Eveline Boucher has a 25 years’ experience in the medical field. She has university qualifications in medecine (Gastroenterology, Hepatology and oncology), and Physics (Master). In past roles she has worked in university hospitals in Paris and Rennes as an hepatologist and in as a medical oncologist in a Comprehensive cancer center in Rennes (France) and participated as principal investigator or sub investigator to more than 50 clinical trials. She is the author of MISPHEC trial.
Prior to joining BTG, she was Medical Director for clinical operation in a French small Pharma company. Within BTG, she serves as the Medical Director in interventional oncology and provides medical input within interventional oncology area. She has a deep experience in liver disease, liver cancers, and digestive cancers and clinical trials. She has been an author of more than 100 medical publications.
Luan’s career in Medical Device started in 2010 serving in a Software Engineering role within the R&D group at Galil Medical. His roles in R&D have spanned across software development, systems engineering, project and program management, and product development activities. Luan currently oversees all product development within the ablation group at BTG. In addition, Luan serves as an active member on the BTG’s IO Portfolio Strategy team.
Luan has been extensively involved with the Cryoablation programs at Galil Medical including the development of the Visual ICE Cryoablation System, Visual ICE MRI Cryoablation System, ICEfx Cryoablation System, IceFORCE 2.1 CX, IcePearl 2.1CX, IceFORCE 2.1 CX L, IcePearl 2.1CX L, IceSphere 1.5 CX, IceSphere S, IceRod 1.5 CX MRI, and IceSphere 1.5 CX MRI.
Yan Rolland is a French interventional radiologist, MD: Rennes University, MR Angiography at 0.5 T, 1991 MBA: Rennes University Contribution to brain vascularisation modelling, 1992 PhD: Rennes University Modelling and medical imaging texture analysis, 1997 Consultant, Radiology department, University Hospital Rennes, 1996 to 2005
Head of the IR department in Comprehensive Cancer Center of Rennes.
Post–doc degree (Habilitation) from Rennes University: research program, conducted in LTSI Inserm UMR 1099 is focused on model-based information processing and decision making with a special focus on liver and prostate
Board of SIAD (French Society of Abdominal Imaging.
Dr. Lely is one of five interventional radiologists and head of the interventional department at VU University Medical Center located in Amsterdam, the Netherlands. Dr. Lely focuses on vascular interventional radiology and his main interests are aortic repair, peripheral arterial/venous diseases and diagnosis and treatment of pulmonary hypertension. He graduated from medicine school in 2001 at the University of Groningen and completed his radiology residency in 2008 at Nieuwegein. In 2009 he finished his fellowship interventional radiology at the VU University Medical Center.
Please select the sessions you wish to attend
IR Trainee Session
Speakers: Pedro Garcia, BTG and Brenda Hall, BTG
Please register via your CIRSE account.
Participation is free of charge.
Speakers: Derek Jerome, Director Clinical & Techical Services, BTG
Please register via your CIRSE account.Participation is free of charge.
Not all products and/or indications are available in your territory. LC Bead™ and Varithena™ are not available outside the US for commercial distribution. DC Bead, LC Bead and Bead Block are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS, the EKOS logo and EkoSonic are trademarks and/or registered trademarks of EKOS Corporation. CenterCross, Microcross and MultiCross are registered trademarks of Roxwood Medical Inc, a BTG International group company. TheraSphere™ is manufactured for Biocompatibles UK Ltd. TheraSphere is a trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. TheraSphere is a registered trademark in the US, EU and certain other territories. Varithena is a trademark of Provensis Ltd and is a registered trademark in the US and certain other territories. ‘Imagine where we can go’, BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. Biocompatibles UK Ltd, EKOS Corporation, Provensis Ltd and Roxwood Medical Inc are BTG International group companies. For full prescribing information please click here Bead Block™, DC Bead™, EKOS™, LC Bead™, TheraSphere™ and Varithena™
© Copyright 2018 BTG International Ltd.